Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: digoxin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

NCT00904176
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Warfarin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 3, 2026, 4:11 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

NCT00504413
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
midazolam(drug), digoxin (drug), Bupropion (drug), Methadone (drug)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 3, 2026, 4:11 PM EDT
Withdrawn Phase 1 Interventional

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

NCT05828303
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
TPX-0005, Metformin Hydrochloride, Digoxin, Rosuvastatin Calcium
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02626234
View directory record Official record
Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
INC280, digoxin, rosuvastatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

NCT02138292
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib (2mg)/Digoxin (.25mg)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Health Adult Volunteers

NCT02273986
View directory record Official record
Conditions
Healthy
Interventions
Digoxin, K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

NCT00650910
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Digoxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Digoxin and PA21

NCT01477411
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
PA21, Digoxin
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 3, 2026, 4:11 PM EDT
Terminated Phase 3 Interventional Results available

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

NCT02620384
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Experimental: Placebo, Experimental: Metolazone
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

NCT06677957
View directory record Official record
Conditions
Healthy Participants
Interventions
Digoxin, Divarasib, Rosuvastatin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 3, 2026, 4:11 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

NCT03113071
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Digoxin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

Digoxin for Recurrent Prostate Cancer

NCT01162135
View directory record Official record
Conditions
Prostate Cancer
Interventions
Digoxin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

NCT06717269
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

NCT07066722
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

NCT01583036
View directory record Official record
Conditions
Epilepsy
Interventions
Digoxin Alone, Digoxin + Retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCT01082289
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Not applicable Interventional

A Trial of Digoxin Before Second-Trimester Abortion

NCT01047748
View directory record Official record
Conditions
Induced Abortion
Interventions
intra-fetal digoxin injection, intra-amniotic digoxin injection
Drug
Lead sponsor
White, Katharine O'Connell, M.D., M.P.H.
Individual
Eligibility
18 Years to 55 Years · Female only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

NCT01436201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Digoxin, Dulaglutide
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 3, 2026, 4:11 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4515100 in Healthy Participants

NCT07339722
View directory record Official record
Conditions
Healthy
Interventions
LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

NCT01763931
View directory record Official record
Conditions
Breast Cancer
Interventions
Digoxin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 3, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 3, 2026, 4:11 PM EDT